PREVENTION OF HEPATITIS B VIRUS CARRIER STATE IN INFANTS ACCORDING TO MATERNAL SERUM LEVELS OF HBV DNA
235 infants of HBeAg-carrier mothers in Hong Kong were assigned to four study groups. Groups I, II, and III received hepatitis-B (HB) vaccine at birth and at 1, 2, and 6 months. Group I also received seven monthly injections of HB immunoglobulin (HBIg), and group II received one HBIg injection at bi...
Gespeichert in:
| Veröffentlicht in: | The Lancet (British edition) 1989-02, Vol.333 (8635), p.406-410 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 410 |
|---|---|
| container_issue | 8635 |
| container_start_page | 406 |
| container_title | The Lancet (British edition) |
| container_volume | 333 |
| creator | Ip, HenriettaM.H. Wong, VivianC.W. Lelie, P.Nico Kuhns, MaryC Reesink, HenkW |
| description | 235 infants of HBeAg-carrier mothers in Hong Kong were assigned to four study groups. Groups I, II, and III received hepatitis-B (HB) vaccine at birth and at 1, 2, and 6 months. Group I also received seven monthly injections of HB immunoglobulin (HBIg), and group II received one HBIg injection at birth. Group III received vaccine only and group IV received placebo for both vaccine and HBIg. At the age of 3 years, all infants of the three treatment groups were significantly protected against the HB virus (HBV) carrier state compared with the placebo group (p |
| doi_str_mv | 10.1016/S0140-6736(89)90003-2 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_198958206</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0140673689900032</els_id><sourcerecordid>8739895</sourcerecordid><originalsourceid>FETCH-LOGICAL-c279t-7bca8a4aca80fe6c8c8b20fee96d8c9efa746c3378ac0090ee87c29e76f964283</originalsourceid><addsrcrecordid>eNqFkNtKw0AQhhdRsFYfQVgEQS-im9MeriRN0zaQJiVJi3fLdruBlNrW3Vbw7d0e0EthmBmYb_5hfgDuXfTiIhe_VsgNkIOJj58oe2YIId_xLkDHDUjghAF5vwSdX-Qa3BiztEyAUdgBzaRMZklep0UOiwEcJZOoTuu0gj04S8tpBeOoLNOkhFUd1QlMcxuDKK8rGMVxUfbTfAjrAo7tsMyjDFZJOR3DzGpm1VGwN4P9PLoFV41YGXV3rl0wHSR1PHKyYpjGUeZIj7CdQ-ZSUBEIm1GjsKSSzj3bKYYXVDLVCBJg6fuECokQQ0pRIj2mCG4YDjzqd8HDSXerN597ZXZ8udnrtT3JXUZZSD2ELRSeIKk3xmjV8K1uP4T-5i7iB0f50VF-sItTxo-Ocs_uPZ7FhZFi1Wixlq35W2Y4ZCxElns7ccp--tUqzY1s1VqqRauV3PHFpv3n0g8f7oFt</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>198958206</pqid></control><display><type>article</type><title>PREVENTION OF HEPATITIS B VIRUS CARRIER STATE IN INFANTS ACCORDING TO MATERNAL SERUM LEVELS OF HBV DNA</title><source>ScienceDirect Journals (5 years ago - present)</source><creator>Ip, HenriettaM.H. ; Wong, VivianC.W. ; Lelie, P.Nico ; Kuhns, MaryC ; Reesink, HenkW</creator><creatorcontrib>Ip, HenriettaM.H. ; Wong, VivianC.W. ; Lelie, P.Nico ; Kuhns, MaryC ; Reesink, HenkW</creatorcontrib><description>235 infants of HBeAg-carrier mothers in Hong Kong were assigned to four study groups. Groups I, II, and III received hepatitis-B (HB) vaccine at birth and at 1, 2, and 6 months. Group I also received seven monthly injections of HB immunoglobulin (HBIg), and group II received one HBIg injection at birth. Group III received vaccine only and group IV received placebo for both vaccine and HBIg. At the age of 3 years, all infants of the three treatment groups were significantly protected against the HB virus (HBV) carrier state compared with the placebo group (p<0·0001); the protective efficacy rates in groups I, II, and III were 87%, 80%, and 65%, respectively. At all times, group I was significantly better protected than group III. In groups III and IV, infants of mothers with serum HBV DNA levels of 5 pg/ml or above were at a significantly higher risk of acquiring the HBV carrier state than those whose mothers had HBV DNA levels below 5 pg/ml. This difference was not significant in groups given HBIg. Of the 183 infants who initially escaped HBV infection, 73 (40%) had transient and 8 (4%) chronic HBV infection between 6 and 36 months. Vaccinated infants who had actively formed anti-HBs remained well protected against the HBV carrier state. However, infants in groups I and II with no active anti-HBs response to vaccine became at risk for the HBV carrier state when the passively acquired anti-HBs antibodies had disappeared. HBIg should be included in HB vaccination schedules for all infants of HBeAg-positive mothers.</description><identifier>ISSN: 0140-6736</identifier><identifier>EISSN: 1474-547X</identifier><identifier>DOI: 10.1016/S0140-6736(89)90003-2</identifier><identifier>CODEN: LANCAO</identifier><language>eng</language><publisher>London: Elsevier Ltd</publisher><subject>Babies ; Biological and medical sciences ; Deoxyribonucleic acid ; DNA ; Hepatitis ; Hepatitis B ; Human viral diseases ; Infants ; Infectious diseases ; Medical sciences ; Vaccines ; Viral cardiopathies ; Viral diseases</subject><ispartof>The Lancet (British edition), 1989-02, Vol.333 (8635), p.406-410</ispartof><rights>1989</rights><rights>1991 INIST-CNRS</rights><rights>Copyright Lancet Ltd. Feb 25, 1989</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c279t-7bca8a4aca80fe6c8c8b20fee96d8c9efa746c3378ac0090ee87c29e76f964283</citedby><cites>FETCH-LOGICAL-c279t-7bca8a4aca80fe6c8c8b20fee96d8c9efa746c3378ac0090ee87c29e76f964283</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/S0140-6736(89)90003-2$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,778,782,3539,27911,27912,45982</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=19659950$$DView record in Pascal Francis$$Hfree_for_read</backlink></links><search><creatorcontrib>Ip, HenriettaM.H.</creatorcontrib><creatorcontrib>Wong, VivianC.W.</creatorcontrib><creatorcontrib>Lelie, P.Nico</creatorcontrib><creatorcontrib>Kuhns, MaryC</creatorcontrib><creatorcontrib>Reesink, HenkW</creatorcontrib><title>PREVENTION OF HEPATITIS B VIRUS CARRIER STATE IN INFANTS ACCORDING TO MATERNAL SERUM LEVELS OF HBV DNA</title><title>The Lancet (British edition)</title><description>235 infants of HBeAg-carrier mothers in Hong Kong were assigned to four study groups. Groups I, II, and III received hepatitis-B (HB) vaccine at birth and at 1, 2, and 6 months. Group I also received seven monthly injections of HB immunoglobulin (HBIg), and group II received one HBIg injection at birth. Group III received vaccine only and group IV received placebo for both vaccine and HBIg. At the age of 3 years, all infants of the three treatment groups were significantly protected against the HB virus (HBV) carrier state compared with the placebo group (p<0·0001); the protective efficacy rates in groups I, II, and III were 87%, 80%, and 65%, respectively. At all times, group I was significantly better protected than group III. In groups III and IV, infants of mothers with serum HBV DNA levels of 5 pg/ml or above were at a significantly higher risk of acquiring the HBV carrier state than those whose mothers had HBV DNA levels below 5 pg/ml. This difference was not significant in groups given HBIg. Of the 183 infants who initially escaped HBV infection, 73 (40%) had transient and 8 (4%) chronic HBV infection between 6 and 36 months. Vaccinated infants who had actively formed anti-HBs remained well protected against the HBV carrier state. However, infants in groups I and II with no active anti-HBs response to vaccine became at risk for the HBV carrier state when the passively acquired anti-HBs antibodies had disappeared. HBIg should be included in HB vaccination schedules for all infants of HBeAg-positive mothers.</description><subject>Babies</subject><subject>Biological and medical sciences</subject><subject>Deoxyribonucleic acid</subject><subject>DNA</subject><subject>Hepatitis</subject><subject>Hepatitis B</subject><subject>Human viral diseases</subject><subject>Infants</subject><subject>Infectious diseases</subject><subject>Medical sciences</subject><subject>Vaccines</subject><subject>Viral cardiopathies</subject><subject>Viral diseases</subject><issn>0140-6736</issn><issn>1474-547X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1989</creationdate><recordtype>article</recordtype><recordid>eNqFkNtKw0AQhhdRsFYfQVgEQS-im9MeriRN0zaQJiVJi3fLdruBlNrW3Vbw7d0e0EthmBmYb_5hfgDuXfTiIhe_VsgNkIOJj58oe2YIId_xLkDHDUjghAF5vwSdX-Qa3BiztEyAUdgBzaRMZklep0UOiwEcJZOoTuu0gj04S8tpBeOoLNOkhFUd1QlMcxuDKK8rGMVxUfbTfAjrAo7tsMyjDFZJOR3DzGpm1VGwN4P9PLoFV41YGXV3rl0wHSR1PHKyYpjGUeZIj7CdQ-ZSUBEIm1GjsKSSzj3bKYYXVDLVCBJg6fuECokQQ0pRIj2mCG4YDjzqd8HDSXerN597ZXZ8udnrtT3JXUZZSD2ELRSeIKk3xmjV8K1uP4T-5i7iB0f50VF-sItTxo-Ocs_uPZ7FhZFi1Wixlq35W2Y4ZCxElns7ccp--tUqzY1s1VqqRauV3PHFpv3n0g8f7oFt</recordid><startdate>19890225</startdate><enddate>19890225</enddate><creator>Ip, HenriettaM.H.</creator><creator>Wong, VivianC.W.</creator><creator>Lelie, P.Nico</creator><creator>Kuhns, MaryC</creator><creator>Reesink, HenkW</creator><general>Elsevier Ltd</general><general>Lancet</general><general>Elsevier Limited</general><scope>IQODW</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QL</scope><scope>7QP</scope><scope>7TK</scope><scope>7U7</scope><scope>7U9</scope><scope>ASE</scope><scope>C1K</scope><scope>FPQ</scope><scope>H94</scope><scope>K6X</scope><scope>K9.</scope><scope>KB~</scope><scope>M7N</scope><scope>NAPCQ</scope></search><sort><creationdate>19890225</creationdate><title>PREVENTION OF HEPATITIS B VIRUS CARRIER STATE IN INFANTS ACCORDING TO MATERNAL SERUM LEVELS OF HBV DNA</title><author>Ip, HenriettaM.H. ; Wong, VivianC.W. ; Lelie, P.Nico ; Kuhns, MaryC ; Reesink, HenkW</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c279t-7bca8a4aca80fe6c8c8b20fee96d8c9efa746c3378ac0090ee87c29e76f964283</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1989</creationdate><topic>Babies</topic><topic>Biological and medical sciences</topic><topic>Deoxyribonucleic acid</topic><topic>DNA</topic><topic>Hepatitis</topic><topic>Hepatitis B</topic><topic>Human viral diseases</topic><topic>Infants</topic><topic>Infectious diseases</topic><topic>Medical sciences</topic><topic>Vaccines</topic><topic>Viral cardiopathies</topic><topic>Viral diseases</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ip, HenriettaM.H.</creatorcontrib><creatorcontrib>Wong, VivianC.W.</creatorcontrib><creatorcontrib>Lelie, P.Nico</creatorcontrib><creatorcontrib>Kuhns, MaryC</creatorcontrib><creatorcontrib>Reesink, HenkW</creatorcontrib><collection>Pascal-Francis</collection><collection>CrossRef</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>British Nursing Index</collection><collection>Environmental Sciences and Pollution Management</collection><collection>British Nursing Index (BNI) (1985 to Present)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>British Nursing Index</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Newsstand Professional</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Nursing & Allied Health Premium</collection><jtitle>The Lancet (British edition)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ip, HenriettaM.H.</au><au>Wong, VivianC.W.</au><au>Lelie, P.Nico</au><au>Kuhns, MaryC</au><au>Reesink, HenkW</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>PREVENTION OF HEPATITIS B VIRUS CARRIER STATE IN INFANTS ACCORDING TO MATERNAL SERUM LEVELS OF HBV DNA</atitle><jtitle>The Lancet (British edition)</jtitle><date>1989-02-25</date><risdate>1989</risdate><volume>333</volume><issue>8635</issue><spage>406</spage><epage>410</epage><pages>406-410</pages><issn>0140-6736</issn><eissn>1474-547X</eissn><coden>LANCAO</coden><abstract>235 infants of HBeAg-carrier mothers in Hong Kong were assigned to four study groups. Groups I, II, and III received hepatitis-B (HB) vaccine at birth and at 1, 2, and 6 months. Group I also received seven monthly injections of HB immunoglobulin (HBIg), and group II received one HBIg injection at birth. Group III received vaccine only and group IV received placebo for both vaccine and HBIg. At the age of 3 years, all infants of the three treatment groups were significantly protected against the HB virus (HBV) carrier state compared with the placebo group (p<0·0001); the protective efficacy rates in groups I, II, and III were 87%, 80%, and 65%, respectively. At all times, group I was significantly better protected than group III. In groups III and IV, infants of mothers with serum HBV DNA levels of 5 pg/ml or above were at a significantly higher risk of acquiring the HBV carrier state than those whose mothers had HBV DNA levels below 5 pg/ml. This difference was not significant in groups given HBIg. Of the 183 infants who initially escaped HBV infection, 73 (40%) had transient and 8 (4%) chronic HBV infection between 6 and 36 months. Vaccinated infants who had actively formed anti-HBs remained well protected against the HBV carrier state. However, infants in groups I and II with no active anti-HBs response to vaccine became at risk for the HBV carrier state when the passively acquired anti-HBs antibodies had disappeared. HBIg should be included in HB vaccination schedules for all infants of HBeAg-positive mothers.</abstract><cop>London</cop><pub>Elsevier Ltd</pub><doi>10.1016/S0140-6736(89)90003-2</doi><tpages>5</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0140-6736 |
| ispartof | The Lancet (British edition), 1989-02, Vol.333 (8635), p.406-410 |
| issn | 0140-6736 1474-547X |
| language | eng |
| recordid | cdi_proquest_journals_198958206 |
| source | ScienceDirect Journals (5 years ago - present) |
| subjects | Babies Biological and medical sciences Deoxyribonucleic acid DNA Hepatitis Hepatitis B Human viral diseases Infants Infectious diseases Medical sciences Vaccines Viral cardiopathies Viral diseases |
| title | PREVENTION OF HEPATITIS B VIRUS CARRIER STATE IN INFANTS ACCORDING TO MATERNAL SERUM LEVELS OF HBV DNA |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-15T12%3A27%3A00IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=PREVENTION%20OF%20HEPATITIS%20B%20VIRUS%20CARRIER%20STATE%20IN%20INFANTS%20ACCORDING%20TO%20MATERNAL%20SERUM%20LEVELS%20OF%20HBV%20DNA&rft.jtitle=The%20Lancet%20(British%20edition)&rft.au=Ip,%20HenriettaM.H.&rft.date=1989-02-25&rft.volume=333&rft.issue=8635&rft.spage=406&rft.epage=410&rft.pages=406-410&rft.issn=0140-6736&rft.eissn=1474-547X&rft.coden=LANCAO&rft_id=info:doi/10.1016/S0140-6736(89)90003-2&rft_dat=%3Cproquest_cross%3E8739895%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=198958206&rft_id=info:pmid/&rft_els_id=S0140673689900032&rfr_iscdi=true |